Skip to content

UVA Protection Factors of SPF 50 and 50+ Face Sunscreens

UVA Protection Factors of SPF 50 and 50+ Face Sunscreens

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06068010
Enrollment
412
Registered
2023-10-05
Start date
2018-04-20
Completion date
2020-12-15
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ultraviolet-Induced Change in Normal Skin

Keywords

sunscreen, UVA protection, ISO 24442:2011, photoprotection

Brief summary

The goal of this observational study is to use the International Organization for Standardization (ISO) 24442:2011 in vivo method for assessment of the Ultraviolet A Protection Factor (UVAPF) of topical sunscreen products in healthy adults. The main question it aims to answer is to determine the degree of UVA-protection against UVA radiation. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.

Detailed description

The objective of the study conducted in accordance with the Declaration of Helsinki and national regulations regarding human studies is to evaluate the UVA protection factor of the investigational products against UVA, according to the ISO 24442:2011 methodology comparatively to a standard product (Standard S2) in healthy adult subjects. Standard reference S2 sunscreen formula is used in a study if any test sample has an expected UVAPF of 12 or above. The mean UVAPF for the reference sample S2 is 12,7. The test result of the reference S2 UVAPF must be between 10,7 and 14,7 or the test is invalid and shall be repeated. The reference S2 may be used to validate any product test. In order to determine the number of subjects, the 95 % confidence interval (CI) shall be taken into account. The 95 % confidence interval should lie within ±17 % of the mean UVAPF, and a minimum of 10 subjects is required.

Interventions

None listed

Sponsors

Cosmetique Active International
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Fitzpatrick skin phototype: II, III or IV * colorimetric Individual Typology Angle (ITA°): 20° to 41° * intact skin on test site

Exclusion criteria

* pregnant or lactating women * subjects using medication with photo-sensitizing potential * subjects receiving chemotherapy or radiotherapy * subjects who have had UV exposure on the back area in the four weeks prior to UVAPF testing

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the protection factor of the investigational product against UVAfrom baseline to 24 hoursThe UVAPF test method uses persistent pigment darkening (PPD) responses of the skin as the end point for evaluating transmitted UVA radiation. The test is restricted to the area of the back of selected human subjects. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure. To determine the UVAPF, incremental series of UVA exposures are delivered to five or six small sub-sites on the skin to induce darkening responses. These responses are visually assessed for pigment darkness 2 h to 24 h after UVA exposure, by the judgement of a trained evaluator.

Countries

Brazil, France, Poland, Romania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026